Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: Results of the EORTC Children Leukemia Cooperative Study 58872

Medical and Pediatric Oncology

Volumn 26, Issue 3, 1996, Pages 173-179

  Béhar, Catherine ^a   Suciu, Stefan ^a   Benoit, Yves ^a   Robert, Alain ^a   Vilmer, Etienne ^a   Boutard, Patrick ^a   Bertrand, Yves ^a   Lutz, Patrick ^a   Ferster, Aline ^a   Tokaji, Erika ^a   Manel, Anne Marie ^a   Solbu, Gabriel ^a   Otten, Jacques ^a  

^a AMERICAN MEMORIAL HOSPITAL   (France)

Author keywords

acute myeloid leukemia; childhood; mitoxantrone; prognostic factors

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CYTARABINE; ETOPOSIDE; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BOLUS INJECTION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOGENETICS; DRUG EFFICACY; FEMALE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEASIBILITY STUDIES; FEMALE; HEART; HEART FUNCTION TESTS; HUMANS; INFANT; LEUKEMIA, MYELOID; MALE; MITOXANTRONE; PROGNOSIS; THIOGUANINE; VINCRISTINE;

EID: 13344277283     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199603)26:3<173::AID-MPO5>3.0.CO;2-H     Document Type: Article

References (29)

1. Steuber P, Civin C, Krischer J, Culbert S, Ragab A, Ruymann F, Ravindranath Y, Leventhal B, Wilkinson R, Vietti: A comparison of induction and maintenance therapy for acute non lymphocytic leukemia in childhood: Results of a pdiatric oncology group study. J Clin Oncol 9:247, 1991.
2. Creutzig U, Ritter J, Schellong G: "Acute Myelogenous Leukemia in Childhood." Berlin Heidelberg: Springer Verlag, 1990.
3. Schenkenberg Todd D, Von Hoff D: Mitoxantrone: A new anti-cancer drug with significant clinical activity. Ann Intern Med 105:67-81, 1986.
4. Durr F: Biological and biochemical effects of mitoxantrone. Semin Oncol 11:3-10, 1984.
5. Poirier TI: Mitoxantrone. Drug Intell Clin Pharm 20:97-105, 1986.
6. Bezwoda WR, Bernasconi C, Hutchinson RM, Winfield DA, De Bock R, Mandelli F: Mitoxantrone for refractory and relapsed acute leukemia. Cancer 66:418-422, 1990.
7. Dutcher JP, Holland JF et al.: Mitoxantrone and ARAC in the treatment of relapsed or refractory ANLL. Symposium on Novantrone. 4th International Symposium on therapy of acute leukemias. Roma, 1987, February 10.
8. Mertelsmann R, Fuhr HG, Burkert M, Herrmann F: Mitoxantrone and high dose cytosine arabinoside for remission induction in refractory and previously untreated acute non-lymphoblastic leukemia. 4th International Symposium on therapy of acute leukemias. Roma, 1987, February 7-12.
9. Hiddemann W: High dose cytosine arabinoside in combination with Mitoxantrone for the treatment of refractory acute myeloid leukemia and lymphoblastic leukemia. Semin Oncol 14:73-77, 1987.
10. Prentice HG: The role of mitoxantrone in the treatment of leukemia. Symposium on Novantrone. 4th International Symposium on therapy of acute leukemias, Roma, 1987, February 10.
11. Starling KA et al.: Mitoxantrone in refractory acute leukemia in children: A phase I study. Investigational New Drugs 3:191-195, 1985.
12. Ungerleider RS et al.: Phase I trial of mitoxantrone in children. Cancer Treatment Reports 69:403-407, 1985.
13. O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, Mc Credie K, Keating M: Mitoxantrone and high dose etoposide for patients with relapsed of refractory acute leukemia. Cancer 48:691-694, 1991.
14. Arlin Z, Case D, Moore J, Wiernik P, Feldman E, and the Lederle Cooperative Group: Randomized multicenter trial of cytosine arabinoside with Mitoxantrone or Daunorubicinc in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 4:177-183, 1990.
15. Dukart G, Posner G, Henry D et al.: Comparative cardiotoxicity of mitoxantrone versus doxorubicin (Abstr.). Proc Am Soc Clin Oncol 5:48, 1986.
16. Crossley RJ: Clinical safety and tolerance of mitoxantrone. Semin Oncol 11 (3 suppl. 1); 54:58, 1984.
17. Creutzig U, Ritter J, Budde M, Riehm H, Henze G, Lampert F, Gerein V, Müller-Weihrich St, Niethammer D, Spaar HJ, Schellong G: Aktuelle Ergbnisse der kooperativen AML-Thera-piestudien bei Kindern: BFM-78 und -83. Klin Pädiat 198:183-190, 1986.
18. Colan S, Borow K, Neumann A: Left ventricular end-systolic wall stress-velocity of fiber shortening relation: A load-independent index of myocardial contractility. JACC 4:715, 1984.
19. Cancer Clinical Trials: Methods and Practice. Buyse ME, Staquet MJ, Sylvester RJ (eds). Oxford: England, Oxford University Press, 1984.
20. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trijillo JM, McCredie KB, Gehan EA, Freireich EJ: Cytogenetic pattern in acute myelogenous leukemia: A major reproductible determinant of outcome. Leukemia 2:403-412, 1988.
21. Amadori S, Testi AM, Arico M, Giuliano M, Madon E, Masera G, Rondelli R, Zanesco L and Mandelli F for the A.E.I.O.P.: Prospective comparative study of bone marrow transplantation and post remission chemotherapy for childhood acute myelogenous leukemia. JCO 11:1046-1054, 1993.
22. Wells RJ, Woods G, Lampkin BC, Nesbit ME, Won Lee J, Buckley JD, Versteeg C, Hammond GD: Impact of high dose Cytarabine and Asparaginase intensification on childhood acute myeloid leukemia: A report from the Childrens Cancer Group. JCO 11:538-545, 1993.
23. Nesbit ME, Bruckley JC, Feig SA, Andersen JR, Lampkin B, Berstein ID, Kim TH, Piomelli B, Kersey JH, Coccia PF, O'Reilly RC, August C, Thomas ED, Hammond GD: Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: A report from the Childrens Cancer Group. JCO 12:127-135, 1994.
24. Creutzig U, Ritter J, Zimmerman M, Schellong G: Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the childhood acute myelogenous leukemia study BFM 87. JCO 11:279-286, 1993.
25. Ehninger G of Mitoxantrone in man. Invest New Drugs 3:109-116, 1985.
26. Smyth JF, MacPherson JS, Warrington PS et al.: The clinical pharmacology of Mitoxantrone. Cancer Chemoth Pharmacol 17: 149-152, 1986.
27. Van Belle SJP, Schoemaker TJ, Verwey SL et al.: Ion-paired high-performance liquid chromatographic determination of Mitoxantrone in physiological fluids. J Chromatography 337:73-80, 1985.
28. Larson RA, Daly KM, Choi Ke et al.: A clinical and pharmacologic study of mitoxantrone in acute non lymphocytic leukemia. J Clin Oncol 5:391-397, 1987.
29. Alberts DS, Peng Y, Leigh S, Davis T, Woodwazrd D: Disposition of Mitoxantrone in cancer patients. Cancer Res 45:1879, 1985.